Wellington Management Group LLP Increases Stock Position in Fulcrum Therapeutics, Inc. $FULC

Wellington Management Group LLP increased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 140.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 285,084 shares of the company’s stock after acquiring an additional 166,484 shares during the quarter. Wellington Management Group LLP owned approximately 0.37% of Fulcrum Therapeutics worth $1,043,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of FULC. Nantahala Capital Management LLC acquired a new stake in Fulcrum Therapeutics during the 2nd quarter worth $20,038,646. Bank of America Corp DE acquired a new position in Fulcrum Therapeutics in the second quarter valued at $3,817,000. ADAR1 Capital Management LLC acquired a new position in Fulcrum Therapeutics in the second quarter valued at $5,728,000. Hsbc Holdings PLC purchased a new stake in shares of Fulcrum Therapeutics in the second quarter valued at about $426,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Fulcrum Therapeutics in the second quarter valued at about $375,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Friday, July 17th. Truist Financial cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research report on Tuesday, June 2nd. Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective for the company. in a research note on Tuesday, June 2nd. HC Wainwright cut Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Tuesday, June 2nd. Finally, Jefferies Financial Group set a $4.00 target price on Fulcrum Therapeutics in a research note on Tuesday, June 2nd. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Fulcrum Therapeutics currently has a consensus rating of “Reduce” and an average target price of $8.20.

Fulcrum Therapeutics Stock Performance

FULC stock opened at $3.80 on Friday. Fulcrum Therapeutics, Inc. has a one year low of $2.83 and a one year high of $15.74. The stock has a market capitalization of $289.93 million, a PE ratio of -3.14 and a beta of 2.59. The company has a fifty day moving average of $3.75 and a 200-day moving average of $5.52.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). Equities analysts forecast that Fulcrum Therapeutics, Inc. will post -0.69 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Alan Ezekowitz sold 18,000 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the completion of the transaction, the director directly owned 10,927 shares of the company’s stock, valued at approximately $39,883.55. This represents a 62.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.30% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.